



# USCDI Task Force 2021 Call #3

Steven Lane, Co-Chair

Terry O'Malley, Co-Chair

February 16, 2021

---

Health Information Technology Advisory Committee

The Office of the National Coordinator for Health Information Technology



# Meeting Agenda

- Call to Order/Roll Call
- Past Meeting Notes
- Task Force Charges
- USCDI TF Recommendations Document
- Tasks 1a and 1b
- TF Schedule/Next Meeting
- Public Comment
- Adjourn

# Task Force Charge

## Overarching charge:

Review and feedback on the Draft USCDI Version 2 content and process

## Specific charges:

### Due

**April 15, 2021**

**1 Evaluate Draft USCDI v2 and provide HITAC with recommendations for:**

**1a** - Data classes and elements from USCDI v1 including applicable standards version updates

**1b** - New data classes and elements from Draft USCDI v2 including applicable standards

**1c** - Level 2 data classes and elements not included in Draft USCDI v2

**2 Evaluate the USCDI expansion process and provide HITAC with recommendations for:**

**September 9, 2021**

**2a**- ONDEC submission system improvements

**2b** - Evaluation criteria and process used to assign levels to submitted data classes and elements

**2c** - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2

**3 Recommend ONC priorities for USCDI version 3 submission cycle**

**September 9, 2021**



# Draft USCDI v2

<b>Allergies and Intolerances</b> <ul style="list-style-type: none"> <li>• Substance (Medication)</li> <li>• Substance (Drug Class)</li> <li>• Reaction</li> </ul>	<b>Diagnostic Imaging</b> <ul style="list-style-type: none"> <li>• Diagnostic Imaging Order</li> <li>• Diagnostic Imaging Report</li> <li>• Diagnostic Imaging Narrative</li> </ul>	<b>Laboratory</b> <ul style="list-style-type: none"> <li>• Tests</li> <li>• Values/Results</li> <li>• Laboratory Report Narrative</li> <li>• Pathology Report Narrative</li> </ul>	<b>Problems</b> <ul style="list-style-type: none"> <li>• Problems</li> <li>• Date of Diagnosis</li> <li>• Date of Resolution</li> </ul>	<b>Vital Signs</b> <ul style="list-style-type: none"> <li>• Diastolic Blood Pressure</li> <li>• Systolic Blood Pressure</li> <li>• Body Height</li> <li>• Body Weight</li> <li>• Heart Rate</li> <li>• Respiratory Rate</li> <li>• Body Temperature</li> <li>• Pulse Oximetry</li> <li>• Inhaled Oxygen Concentration</li> <li>• BMI Percentile (2-20 Years)</li> <li>• Weight-for-length Percentile (Birth-36 Months)</li> <li>• Occipital-frontal Head Circumference Percentile (Birth-36 Months)</li> </ul>
<b>Assessment and Plan of Treatment</b> <ul style="list-style-type: none"> <li>• Assessment and Plan of Treatment</li> </ul>	<b>Encounter Information</b> <ul style="list-style-type: none"> <li>• Encounter Type</li> <li>• Encounter Diagnosis</li> <li>• Encounter Time</li> </ul>	<b>Medications</b> <ul style="list-style-type: none"> <li>• Medications</li> </ul>	<b>Procedures</b> <ul style="list-style-type: none"> <li>• Procedures</li> </ul>	
<b>Care Team Members</b> <ul style="list-style-type: none"> <li>• Care Team Members</li> <li>• Provider Name</li> <li>• Provider Identifier</li> </ul>	<b>Goals</b> <ul style="list-style-type: none"> <li>• Patient Goals</li> </ul>	<b>Patient Demographics</b> <ul style="list-style-type: none"> <li>• First Name</li> <li>• Last Name</li> <li>• Previous Name</li> <li>• Middle Name (incl. middle initial)</li> <li>• Suffix</li> <li>• Birth Sex</li> <li>• Date of Birth</li> <li>• Race</li> <li>• Ethnicity</li> <li>• Preferred Language</li> <li>• Current Address</li> <li>• Previous Address</li> <li>• Phone Number</li> <li>• Phone Number Type</li> <li>• Email Address</li> </ul>	<b>Provenance</b> <ul style="list-style-type: none"> <li>• Author Time Stamp</li> <li>• Author Organization</li> </ul>	
<b>Clinical Notes</b> <ul style="list-style-type: none"> <li>• Consultation Note</li> <li>• Discharge Summary Note</li> <li>• History &amp; Physical</li> <li>• Procedure Note</li> <li>• Progress Note</li> </ul>	<b>Health Concerns</b> <ul style="list-style-type: none"> <li>• Health Concerns</li> </ul>		<b>Smoking Status</b> <ul style="list-style-type: none"> <li>• Smoking Status</li> </ul>	
	<b>Immunizations</b> <ul style="list-style-type: none"> <li>• Immunizations</li> </ul>		<b>Unique Device Identifier(s) for a Patient's Implantable Device(s)</b> <ul style="list-style-type: none"> <li>• Unique Device Identifier(s) for a Patient's Implantable Device(s)</li> </ul>	

Key  New Data Class or Element  
 Data Element reclassified

# Task Force Charge 1a

- |   | <b><u>Due</u></b>        |
|---|--------------------------|
| <b>1 Evaluate Draft USCDI v2 and provide HITAC with recommendations for:</b>                              | <b>April 15, 2021</b>    |
| <b>1a - Data classes and elements from USCDI v1 including applicable standards version updates</b>        |                          |
| <b>1b - New data classes and elements from Draft USCDI v2 including applicable standards</b>              |                          |
| <b>1c - Level 2 data classes and elements not included in Draft USCDI v2</b>                              |                          |
| <b>2 Evaluate the USCDI expansion process and provide HITAC with recommendations for:</b>                 | <b>September 9, 2021</b> |
| <b>2a- ONDEC submission system improvements</b>   |                          |
| <b>2b - Evaluation criteria and process used to assign levels to submitted data classes and elements</b>  |                          |
| <b>2c - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2</b> |                          |
| <b>3 Recommend ONC priorities for USCDI version 3 submission cycle</b>                                    | <b>September 9, 2021</b> |

# Draft USCDI version 2 Reclassified Clinical Note Data Elements

- Clinical Notes

- Consultation Note
- Discharge Summary Note
- History & Physical
- Procedure Note
- Progress Note
- Diagnostic Imaging Narrative
- Laboratory Report Narrative
- Pathology Report Narrative

Reclassified



- Diagnostic Imaging

- Diagnostic Imaging Narrative

- Laboratory

- Laboratory Report Narrative
- Pathology Report Narrative

# Task 1a –Data Elements and Classes from USCDI v1

- Comments
- Additions
- Clarifications/Modifications

# Task Force Charge

## Due

**April 15, 2021**

**1 Evaluate Draft USCDI v2 and provide HITAC with recommendations for:**

**1a** - Data classes and elements from USCDI v1 including applicable standards version updates

**1b** - New data classes and elements from Draft USCDI v2 including applicable standards

**1c** - Level 2 data classes and elements not included in Draft USCDI v2

**2 Evaluate the USCDI expansion process and provide HITAC with recommendations for:**

**September 9, 2021**

**2a**- ONDEC submission system improvements

**2b** - Evaluation criteria and process used to assign levels to submitted data classes and elements

**2c** - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2

**3 Recommend ONC priorities for USCDI version 3 submission cycle**

**September 9, 2021**

# Draft USCDI version 2

## New Data Classes and Elements

- **Care Team Members**
  - Provider Name
  - Provider Identifier
- **Diagnostic Imaging**
  - Diagnostic Imaging Order
  - Diagnostic Imaging Report
- **Encounter Information**
  - Encounter Type
  - Encounter Diagnosis
  - Encounter Time
- **Problems**
  - Date of Diagnosis
  - Date of Resolution

# Task 1b – New Data Elements and Classes

- Comments
- Additions
- Clarifications/Modifications

## Next TF Meetings

- February 23, 2021      10:30a - 12:00p ET
- March 2, 2021      10:30a - 12:00p ET
- March 9, 2021      10:30a - 12:00p ET
- March 16, 2021      10:30a - 12:00p ET

## Public Comment

To make a comment please call:  
**Dial: 1-877-407-7192**

*(Once connected, press “\*1” to speak)*

**All public comments will be limited to three minutes.**

You may enter a comment in the  
**“Public Comment”** field below this presentation.

Or, email your public comment to [onc-hitac@accelsolutionsllc.com](mailto:onc-hitac@accelsolutionsllc.com).

*Written comments will not be read at this time,  
but they will be delivered to members of the Task Force and made part of the Public Record.*



# Questions?



**Meeting  
Adjourned**